Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 107-113

  Calderone, Vincenzo ^a   Testai, Lara ^a   Martelli, Alma ^a   La Motta, Concettina ^a   Sartini, Stefania ^a   Da Settimo, Federico ^a   Breschi, Maria C ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Aldose reductase; Antioxidant effect; Cardiovascular complications; Diabetes; Myocardial ischaemia

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; PYRIDOL[1,2-A]PYRIMIDINE 4 ONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; NONHUMAN; RAT; REPERFUSION INJURY; TREATMENT OUTCOME;

ALDEHYDE REDUCTASE; ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PYRIDINES; PYRIMIDINONES; RATS; RATS, WISTAR; RHODANINE; THIAZOLIDINES;

EID: 77949506243     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.01.0012     Document Type: Article

References (27)

1. Srivastava SK et al. Activation of human erythrocyte, brain, aorta, muscle, and ocular tissue aldose reductase. Metabolism 1986; 35: 114-118.
2. Williamson JR et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813.
3. Busik JV et al. Glucose-specific regulation of aldose reductase in Capan-1 human pancreatic duct cells in vitro. J Clin Invest 1997; 100: 1685-1692.
4. Iwata K et al. The activity of aldose reductase is elevated in diabetic mouse heart. J Pharmacol Sci 2007; 103: 408-416.
5. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21-33.
6. Ramasamy R et al. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol 1998; 275: H195-H203.
7. Iwata K et al. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci 2006; 102: 37-46.
8. Hamilton SJ et al. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2007; 4: 89-102.
9. Hartge MM et al. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007; 4: 84-88.
10. Vander Jagt DL et al. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 1995; 1249: 117-126.
11. Lucas DT, Szweda LI. Cardiac reperfusion injury: aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci USA 1998; 95: 510-514.
12. Eaton P et al. Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am J Physiol 1999; 276: H935-H943.
13. Shinmura K et al. Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning. Circ Res 2002; 91: 240-246.
14. Kador PF, Kinoshita JH. Role of aldose reductase in the development of diabetes associated complications. Am J Med 1985; 79: 8-12.
15. Kador PF. The role of aldose reductase in the development of diabetic complications. Med Res Rev 1988; 8: 325-352.
16. Ramasamy R et al. Aldose reductase inhibition protects diabetic and non-diabetic rat hearts from ischemic injury. Diabetes 1997; 46: 292-300.
17. Ananthakrishnan R et al. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2009; 296: H333-H341.
18. Testai L et al. Cardiac ATP-sensitive potassium channels: a potential target for an anti-ischaemic pharmacological strategy. Cardiovasc Hematol Agents Med Chem 2007; 5: 79-90.
19. Tracey WR et al. Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury. Am J Physiol Heart Circ Physiol 2000; 279: H1447-H1452.
20. Hwang YC et al. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J 2002; 16: 243-245.
21. Hwang YC et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 2004; 18: 1192-1199.
22. Kowluru RA, Kennedy A. Therapeutic potential of antioxidants and diabetic retinopathy. Expert Opin Investig Drugs 2001; 10: 1665-1676.
23. Dickinson PJ et al. Neurovascular disease, antioxidants and glycation in diabetes. Diabetes Metab Res Rev 2002; 18: 260-272.
24. La Motta C et al. Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity. J Med Chem 2007; 50: 4917-4927.
25. Calderone V et al. Anti-ischemic properties of a new spirocyclic benzopyran activator of the cardiac mito-K(ATP) channel. Biochem Pharmacol 2010; 79: 39-47.
26. Srivastava SK et al. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005; 26: 380-392.
27. Stefek M et al. Carboxymethilated pyridoindole antioxidants as aldose reductase inhibitors: synthesis, activity, portioning and molecular modeling. Bioorg Med Chem 2009; 16: 4908-4920.